Get started
Author

Emilie Schindler

Observed names: E Schindler, E. Schindler
ORCID: 0000-0002-4654-1131
Observed ORCID: 0000-0002-4654-1131
OpenAlex ID: A5029628625
Population pharmacokinetic–pharmacodynamic modelling in oncology: a tool for predicting clinical response
2013 · Brendan C. Bender, Emilie Schindler, et al. · British Journal of Clinical Pharmacology · 99
PDF
Forward and reverse translational approaches to predict efficacy of neutralizing respiratory syncytial virus (RSV) antibody prophylaxis
2021 · Brian M. Maas, Jos Lommerse, et al. · EBioMedicine · 58
A pharmacokinetic binding model for bevacizumab and VEGF165 in colorectal cancer patients
2015 · Eirini Panoilia, Emilie Schindler, et al. · Cancer Chemotherapy and Pharmacology · 54
PDF
A Minimal Continuous-Time Markov Pharmacometric Model
2017 · Emilie Schindler, Mats O. Karlsson · The AAPS Journal · 21
PDF
A Pharmacometric Analysis of Patient-Reported Outcomes in Breast Cancer Patients Through Item Response Theory
2018 · Emilie Schindler, Lena E. Friberg, et al. · Pharmaceutical Research · 18
PDF
PK‐PD modeling of individual lesion FDG‐PET response to predict overall survival in patients with sunitinib‐treated gastrointestinal stromal tumor
2016 · E Schindler, MA Amantea, et al. · CPT Pharmacometrics & Systems Pharmacology · 18
PDF
A Pharmacometric Framework for Axitinib Exposure, Efficacy, and Safety in Metastatic Renal Cell Carcinoma Patients
2017 · E Schindler, MA Amantea, et al. · CPT Pharmacometrics & Systems Pharmacology · 17
PDF
Pharmacometric Modeling of Liver Metastases' Diameter, Volume, and Density and Their Relation to Clinical Outcome in Imatinib‐Treated Patients With Gastrointestinal Stromal Tumors
2017 · E Schindler, SM Krishnan, et al. · CPT Pharmacometrics & Systems Pharmacology · 16
PDF
Population PK and Semimechanistic PK/PD Modeling and Simulation of Relugolix Effects on Testosterone Suppression in Men with Prostate Cancer
2022 · Tien‐Yi Lee, Philippe Bernard Pierrillas, et al. · Clinical Pharmacology & Therapeutics · 14
PDF
Response‐Based Dosing for Ponatinib: Model‐Based Analyses of the Dose‐Ranging OPTIC Study
2023 · Michael J. Hanley, Paul Diderichsen, et al. · Clinical Pharmacology & Therapeutics · 13
PDF
Intravenous and Subcutaneous Administration of RG6234, a Novel GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Biomarker Results from a Phase I Study
2022 · Iryna Dekhtiarenko, Iva Lelios, et al. · Blood · 9
Pharmacometric Analysis of the Relationship Between Absolute Lymphocyte Count and Expanded Disability Status Scale and Relapse Rate, Efficacy End Points, in Multiple Sclerosis Trials
2018 · A.M. Novakovic, A. Thorsted, et al. · The Journal of Clinical Pharmacology · 9
PBPK Modeling of Entrectinib and Its Active Metabolite to Derive Dose Adjustments in Pediatric Populations Co‐Administered with CYP3A4 Inhibitors
2024 · Kenichi Umehara, Neil Parrott, et al. · Clinical Pharmacology & Therapeutics · 8
PDF
An overview of statistical methods for biomarkers relevant to early clinical development of cancer immunotherapies
2024 · David Dejardin, Anton Kraxner, et al. · Frontiers in Immunology · 7
PDF
Simulation‐based evaluation of the Pharmpy Automatic Model Development tool for population pharmacokinetic modeling in early clinical drug development
2024 · Zrinka Duvnjak, Franziska Schaedeli Stark, et al. · CPT Pharmacometrics & Systems Pharmacology · 5
PDF
Abstract 843: Development of a quantitative systems pharmacology model for clinical dose and schedule optimization of RG6234, a T-cell engaging antibody targeting GPRC5D in multiple myeloma
2023 · Cristina C. Santini, Emilie Schindler, et al. · Cancer Research · 2
Model‐informed drug development to support nemolizumab clinical development in adults and adolescents with moderate to severe atopic dermatitis
2026 · Floris Fauchet, Anna Largajolli, et al. · British Journal of Clinical Pharmacology · 1
505 An ex-vivo reverse translational model demonstrates intact T cell functionality independently of clinical response to a T cell bispecific in multiple myeloma patients
2025 · Carmen Yong, Iryna Dekhtiarenko, et al. · Regular and Young Investigator Award Abstracts · 1
PDF
P-075 Development of a Quantitative Systems Pharmacology (QSP) model describing T-cell bispecific induced immune activation and Multiple Myeloma (MM) cell killing
2024 · Cristina Santini, Emilie Schindler, et al. · Clinical Lymphoma Myeloma & Leukemia · 1
Forimtamig, a GPRC5DxCD3 bispecific antibody with a novel 2:1 format, in relapsed/refractory multiple myeloma
2026 · Anna Caroline Hasselbalch, Simon J. Harrison, et al. · Blood Advances
PDF
T-cell dynamics, CD8/NK ratio and tumor survival hallmarks determine response to T-cell bispecific forimtamig in myeloma
2026 · Iryna Dekhtiarenko, Jan Attig, et al. · Blood Advances
PDF
A modified Bayesian information criterion (mBIC) with multiple testing correction for population pharmacokinetic model building
2024 · Andrew C. Hooker, Xiaomei Chen, et al.
998. Forward and Reverse Translational Approaches to Predict Efficacy of the Neutralizing Respiratory Syncytial Virus (RSV) Antibody MK-1654
2021 · Brian M Maas, Jos Lommerse, et al. · Open Forum Infectious Diseases
Pharmacometrics to improve clinical benefit assessment in oncology
2018 · Emilie Schindler · KTH Publication Database DiVA (KTH Royal Institute of Technology)
Works count: 24
Citation count: 371
H-index: 10
I10-index: 10
Year
Topic
Type